BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
CymaBay Therapeutics, Inc. (Nasdaq – CBAY)
Under the terms of the agreement, CymaBay Therapeutics will be acquired by Gilead Sciences, Inc. (Nasdaq - GILD) for $32.50 per share in cash or a total equity value of $4.3 billion. The investigation concerns whether the CymaBay Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Gilead Sciences is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/cymabay-therapeutics-inc-nasdaq-cbay/.
Masonite International ...